Publications by authors named "Ilene Weitz"

Claim this Profile
N
Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.
Gloria F Gerber, Catherine M Broome, Ilene C Weitz

Clin Adv Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement inhibitors: a significant advance in the treatment of PNH.
Ilene C Weitz

Clin Adv Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monotherapy with terminal pathway C5 inhibitors.
Ilene C Weitz

Clin Adv Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical approach to managing PNH: Q&A.
Gloria F Gerber, Ilene C Weitz, Catherine M Broome

Clin Adv Hematol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
David Dingli, Carlos De Castro Iii, Jamie Koprivnikar, Austin Kulasekararaj, Jaroslaw Maciejewski, Ilene Weitz

Hematology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma, Ilene C Weitz

EClinicalMedicine· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension.
Alexander Röth, Catherine M Broome, Wilma Barcellini, Bernd Jilma, Quentin A Hill, Ilene C Weitz

EClinicalMedicine· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.
Alexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, David J Kuter, Ilene C Weitz

Ann Hematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.
Alexander Röth, Catherine M Broome, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, Ilene C Weitz

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP.
Ilene Ceil Weitz, Howard Allen Liebman

Br J Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Ilene C Weitz

Am J Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.
Austin G Kulasekararaj, David J Kuter, Morag Griffin, Ilene C Weitz, Alexander Röth

Blood Rev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Alexander Röth, Catherine M Broome, Wilma Barcellini, Bernd Jilma, Quentin A Hill, Ilene C Weitz

Eur J Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.
Ilene Ceil Weitz

J Blood Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Alexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, David J Kuter, Ilene C Weitz

Ann Hematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma, Ilene C Weitz

Blood· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
Régis Peffault de Latour, Jeff Szer, Ilene C Weitz, Alexander Röth, Britta Höchsmann

Lancet Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Alexander Roth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Ilene C Weitz

Haematologica· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.
Jonathan Barratt, Ilene Weitz

Front Immunol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Anastasia Martynova, Victor Chiu, Melissa Mert, David Hermel, Ilene Ceil Weitz

Ann Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome.
Edward Chau, Shiqian Li, Peter Z Xu, Grace X Li, Wesley Ghasem, Ilene C Weitz

JACC Case Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Peter Hillmen, Jeff Szer, Ilene Weitz, Alexander Röth, Britta Höchsmann

N Engl J Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Ioannis Tomazos, J Rafael Sierra, Karissa M Johnston, Antoinette Cheung, Robert A Brodsky, Ilene C Weitz

Hematology· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
Carlos de Castro, Federico Grossi, Ilene Ceil Weitz, Jaroslaw Maciejewski, Vivek Sharma

Am J Hematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review.
Melody Hermel, David Hermel, Saif Azam, Jerold Shinbane, Annahita Sarcon, Ilene Weitz

EJHaem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis